Home
EYEN
EYEN News

Latest Eyenovia Inc. (EYEN) News on June 1, 2025

Eyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial Results

GlobeNewswire

13 days ago

Eyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial Results

Eyenovia Provides Development Update on Optejet User Filled Device (UFD)

GlobeNewswire

2 months ago

Eyenovia Provides Development Update on Optejet User Filled Device (UFD)

Eyenovia Shares Drop 14% Amid Betaliq Merger Talks

GuruFocus.com

2 months ago

Eyenovia Shares Drop 14% Amid Betaliq Merger Talks

Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq

GlobeNewswire

2 months ago

Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq

Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements

GlobeNewswire

3 months ago

Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements

Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives

GlobeNewswire

3 months ago

Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives

Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device

GlobeNewswire

4 months ago

Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device

MT Newswires

4 months ago

Top Midday Decliners

Eyenovia Announces 1-for-80 Reverse Stock Split

GlobeNewswire

4 months ago

Eyenovia Announces 1-for-80 Reverse Stock Split

Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote “FOR” Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders

GlobeNewswire

5 months ago

Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote “FOR” Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders

MT Newswires

5 months ago

Eyenovia Hires Chardan as Financial Adviser to Review Strategic Options

Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives

GlobeNewswire

5 months ago

Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives

MT Newswires

6 months ago

Eyenovia Signs $1.9 Million Registered Direct Offering

Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering

GlobeNewswire

6 months ago

Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering

Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering

GlobeNewswire

6 months ago

Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering

Eyenovia taking additional actions to reduce personnel-related costs by over 70%

TipRanks

6 months ago

Eyenovia taking additional actions to reduce personnel-related costs by over 70%

MT Newswires

6 months ago

Sector Update: Health Care Stocks Advance Premarket Friday

MT Newswires

6 months ago

Eyenovia Says Avenue Capital Agrees to Potential Loan Restructuring; Shares Up Pre-Bell

Eyenovia Provides Update on Restructuring Efforts

GlobeNewswire

6 months ago

Eyenovia Provides Update on Restructuring Efforts

MT Newswires

6 months ago

Eyenovia Stock Plunges After Firm Reports Potential Restructuring Talks

Eyenovia downgraded to Neutral from Buy at H.C. Wainwright

TipRanks

6 months ago

Eyenovia downgraded to Neutral from Buy at H.C. Wainwright

Eyenovia Stock Tumbles on Termination of Phase III Myopia Study

Zacks

6 months ago

Eyenovia Stock Tumbles on Termination of Phase III Myopia Study

Eyenovia stock plummets following Phase III myopia trial failure

Clinical Trials Arena

6 months ago

Eyenovia stock plummets following Phase III myopia trial failure

MT Newswires

7 months ago

Sector Update: Health Care Stocks Slide Late Afternoon

MT Newswires

7 months ago

Sector Update: Health Care

MT Newswires

7 months ago

Update: Eyenovia Considers 'Options' After Dispensing Platform Study Fails to Meet Target -- Shares Drop

Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline

Benzinga

7 months ago

Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline

MT Newswires

7 months ago

Sector Update: Health Care Stocks Decline Premarket Friday

MT Newswires

7 months ago

Top Premarket Decliners

MT Newswires

7 months ago

Eyenovia to Consider 'Strategic Options' After Phase 3 Study Fails to Meet Primary Endpoint

Eyenovia Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.

7 months ago

Eyenovia Third Quarter 2024 Earnings: Misses Expectations

Eyenovia Inc (EYEN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

GuruFocus.com

7 months ago

Eyenovia Inc (EYEN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

Eyenovia, Inc. (EYEN) Reports Q3 Loss, Misses Revenue Estimates

Zacks

7 months ago

Eyenovia, Inc. (EYEN) Reports Q3 Loss, Misses Revenue Estimates

Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

7 months ago

Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th

GlobeNewswire

7 months ago

Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th

Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet®

GlobeNewswire

7 months ago

Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet®

Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo

GlobeNewswire

8 months ago

Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo

Here's Why Eyenovia (EYEN) Is a Great 'Buy the Bottom' Stock Now

Zacks

8 months ago

Here's Why Eyenovia (EYEN) Is a Great 'Buy the Bottom' Stock Now

Eyenovia Inc (EYEN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

GuruFocus.com

8 months ago

Eyenovia Inc (EYEN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device

GlobeNewswire

8 months ago

Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device

MT Newswires

8 months ago

Eyenovia Prices $4 Million Direct Offering

Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering

GlobeNewswire

8 months ago

Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering

MT Newswires

8 months ago

Eyenovia's Clobetasol Now Available in US After FDA Approval; Shares Rise Pre-Bell

Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery

GlobeNewswire

8 months ago

Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery

Formosa Pharma ships APP13007 ophthalmic drug to US

Pharmaceutical Technology

9 months ago

Formosa Pharma ships APP13007 ophthalmic drug to US

Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S.

GlobeNewswire

9 months ago

Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S.

Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer

GlobeNewswire

9 months ago

Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer

MT Newswires

9 months ago

Eyenovia Raises $5.1 Million From Public Offering

Eyenovia Announces Closing of Public Offering

GlobeNewswire

9 months ago

Eyenovia Announces Closing of Public Offering

MT Newswires

9 months ago

Top Midday Decliners

MT Newswires

9 months ago

Eyenovia Prices $5.14 Million Public Offering; Shares Fall

Eyenovia Announces Pricing of $5.14 Million Public Offering

GlobeNewswire

9 months ago

Eyenovia Announces Pricing of $5.14 Million Public Offering

MT Newswires

9 months ago

Eyenovia Plans Share Offering; Stocks Falls After Hours

Eyenovia, Inc. Announces Proposed Public Offering

GlobeNewswire

9 months ago

Eyenovia, Inc. Announces Proposed Public Offering

Eyenovia (EYEN) Upgraded to Buy: Here's What You Should Know

Zacks

10 months ago

Eyenovia (EYEN) Upgraded to Buy: Here's What You Should Know

Eyenovia to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

GlobeNewswire

10 months ago

Eyenovia to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Eyenovia, Inc. (EYEN) Reports Q2 Loss, Misses Revenue Estimates

Zacks

10 months ago

Eyenovia, Inc. (EYEN) Reports Q2 Loss, Misses Revenue Estimates

Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

10 months ago

Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Eyenovia to Report Second Quarter 2024 Results on Monday, August 12th

GlobeNewswire

10 months ago

Eyenovia to Report Second Quarter 2024 Results on Monday, August 12th

Eyenovia and Formosa Pharmaceuticals Initiate Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S.

GlobeNewswire

10 months ago

Eyenovia and Formosa Pharmaceuticals Initiate Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S.

Formosa Pharma and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension, 0.05%, for the treatment of Acute Dry Eye Disease in United States

PR Newswire

10 months ago

Formosa Pharma and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension, 0.05%, for the treatment of Acute Dry Eye Disease in United States

Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease

GlobeNewswire

10 months ago

Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease

MT Newswires

10 months ago

Eyenovia Shares Fall After Regaining Compliance With Nasdaq Minimum Bid Price Rule

Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease

GlobeNewswire

10 months ago

Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease

Eyenovia Insiders Enjoying US$200k Appreciation On US$1.34m Investment

Simply Wall St.

a year ago

Eyenovia Insiders Enjoying US$200k Appreciation On US$1.34m Investment

MT Newswires

a year ago

NovaBay Pharmaceuticals, Eyenovia Begin Co-Promotion Deal Activities

Business Wire

a year ago

NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities

Eyenovia Announces Pricing of $5M Registered Direct Offering

GlobeNewswire

a year ago

Eyenovia Announces Pricing of $5M Registered Direct Offering

All You Need to Know About Eyenovia (EYEN) Rating Upgrade to Buy

Zacks

a year ago

All You Need to Know About Eyenovia (EYEN) Rating Upgrade to Buy

GuruFocus.com

a year ago

Eyenovia Inc (EYEN) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and ...

Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol

GlobeNewswire

a year ago

Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol

Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th

GlobeNewswire

a year ago

Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th

Formosa and Tabuk sign deal for FDA-approved ophthalmic suspension

Pharmaceutical Technology

a year ago

Formosa and Tabuk sign deal for FDA-approved ophthalmic suspension

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension

GlobeNewswire

a year ago

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension

Eyenovia (EYEN) Down 18% on Disappointing Corporate Update

Zacks

a year ago

Eyenovia (EYEN) Down 18% on Disappointing Corporate Update

Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities

GlobeNewswire

a year ago

Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities

Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings

GlobeNewswire

a year ago

Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings

Thomson Reuters StreetEvents

a year ago

Q4 2023 NovaBay Pharmaceuticals Inc Earnings Call

Eyenovia, Inc. (NASDAQ:EYEN) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

Eyenovia, Inc. (NASDAQ:EYEN) Q4 2023 Earnings Call Transcript

Thomson Reuters StreetEvents

a year ago

Q4 2023 Eyenovia Inc Earnings Call

Eyenovia, Inc. (EYEN) Reports Q4 Loss, Misses Revenue Estimates

Zacks

a year ago

Eyenovia, Inc. (EYEN) Reports Q4 Loss, Misses Revenue Estimates

Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals

GlobeNewswire

a year ago

NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals

Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th

GlobeNewswire

a year ago

Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th

Beyond Cataract Surgery: Analyst Highlights Broader Market Potential For Eyenovia/Formosa's Steroid For Post-Eye Surgery Pain, Inflammation

Benzinga

a year ago

Beyond Cataract Surgery: Analyst Highlights Broader Market Potential For Eyenovia/Formosa's Steroid For Post-Eye Surgery Pain, Inflammation

Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery

GlobeNewswire

a year ago

Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery

Reuters

a year ago

UPDATE 2-US FDA approves Eyenovia's eye drug, Formosa Pharma says

Reuters

a year ago

US FDA approves Eyenovia's eye drug, Formosa Pharma says

retail investors who own 56% along with institutions invested in Eyenovia, Inc. (NASDAQ:EYEN) saw increase in their holdings value last week

Simply Wall St.

a year ago

retail investors who own 56% along with institutions invested in Eyenovia, Inc. (NASDAQ:EYEN) saw increase in their holdings value last week

Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility

GlobeNewswire

a year ago

Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility

Why Haoxi Health Technology Limited (NASDAQ:HAO) Looks Like A Quality Company

Simply Wall St.

a year ago

Why Haoxi Health Technology Limited (NASDAQ:HAO) Looks Like A Quality Company

American Public University System and Ardent Health Services Partner to Help Ardent Team Members Earn Degrees

PR Newswire

a year ago

American Public University System and Ardent Health Services Partner to Help Ardent Team Members Earn Degrees

Flux Power Holdings (NASDAQ:FLUX) adds US$8.4m to market cap in the past 7 days, though investors from three years ago are still down 71%

Simply Wall St.

a year ago

Flux Power Holdings (NASDAQ:FLUX) adds US$8.4m to market cap in the past 7 days, though investors from three years ago are still down 71%

Invitae sells reproductive health assets amid liquidity concerns

MedTech Dive

a year ago

Invitae sells reproductive health assets amid liquidity concerns

At US$16.29, Is DLH Holdings Corp. (NASDAQ:DLHC) Worth Looking At Closely?

Simply Wall St.

a year ago

At US$16.29, Is DLH Holdings Corp. (NASDAQ:DLHC) Worth Looking At Closely?

Q3 Modern Fast Food Earnings: Wingstop (NASDAQ:WING) Earns Top Marks

StockStory

a year ago

Q3 Modern Fast Food Earnings: Wingstop (NASDAQ:WING) Earns Top Marks

Beverages and Alcohol Stocks Q3 Highlights: Anheuser-Busch (NYSE:BUD)

StockStory

a year ago

Beverages and Alcohol Stocks Q3 Highlights: Anheuser-Busch (NYSE:BUD)

Myomo Reports Preliminary Fourth Quarter Revenue and Backlog

Business Wire

a year ago

Myomo Reports Preliminary Fourth Quarter Revenue and Backlog

Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada

GlobeNewswire

a year ago

Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada

Globalink Investment Inc. Announces Extension of the Deadline to Complete a Business Combination to February 9, 2024

GlobeNewswire

a year ago

Globalink Investment Inc. Announces Extension of the Deadline to Complete a Business Combination to February 9, 2024

Share on Social Networks: